Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAA therapy for HCV-negative recipients of HCV-positive kidneys
NCT04320290Phase 4Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- May 2020
- Primary completion
- Jun 2020
01
Overview
Phase 4, open-label, single-arm trial in hepatitis C (HCV), sponsored by Massachusetts General Hospital. Primary endpoints: Undetectable Hepatitis C Virus RNA and Rate of Serious and non-serious adverse events. Planned start May 2020; status: withdrawn.
02
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT04320290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04320290.